Opinión de expertos sobre el uso de la oxibutinina transdérmica en España para el tratamiento de la vejiga hiperactiva en adultos

Müller Arteaga, Carlos; Arlandis Guzmán, Salvador; Lorenzo Gómez, María Fernanda; Errando Smet, Carlos; González López, Raquel; Cambronero Santos, Javier; Gutiérrez Baños, José Luis; Sánchez Marcos, Manuel; Ortiz Gamiz, Antonio; Merino Salas, Sergio; Martínez Rodriguez, Roberto; Olano Grasa, Ivan.
Arch. esp. urol. (Ed. impr.) ; 69(9): 613-620, nov. 2016. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-157665

Documentos relacionados

  1. Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis.
  2. Anticholinergic therapy: do the patients take the pills prescribed?
  3. Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder.
  4. Anticholinergics/antimuscarinic drugs in asthma.
  5. A Comparison of U.S. Individual and Family Plan Medication Coverage for Overactive Bladder.
  6. Impact of sympathetic dysfunction in the etiology of overactive bladder in women: A preliminary study.
  7. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
  8. Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients.
  9. Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial.
  10. Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder.